Rehabilitation & Neurological Services LLC
Rehabilitation & Neurological Services LLC was paid $1.25M by Medicaid between Jan 2018 and Dec 2024, across 41 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 22% of everything it billed.
33Billing provider infoREHABILITATION & NEUROLOGICAL SERVICES LLC
HUNTSVILLE, AL 35805
HUNTSVILLE, AL 35805
33aNPI1548240179assigned 01/19/2006
33bProvider typeSpecialist
28Total paid$1.25M
24GClaims66,689
24DCodes billed41
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in Alabama
Rank by total paid#16 of 162
Median peer was paid$49K
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,210 | $198K | |
| 2019 | 14,336 | $255K | |
| 2020 | 12,702 | $193K | |
| 2021 | 10,820 | $202K | |
| 2022 | 5,167 | $133K | |
| 2023 | 5,991 | $179K | |
| 2024incomplete | 3,463 | $94K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 22% | 5,747 | 5,136 | $275K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 3,650 | 3,158 | $152K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 10% | 2,599 | 2,347 | $126K |
| 72270 | 9.5% | 1,017 | 788 | $119K | |
| 64493 | 7.8% | 2,277 | 831 | $97K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 7.1% | 671 | 622 | $89K |
| 64495 | 5.2% | 2,017 | 759 | $65K | |
| 27096 | 4.8% | 540 | 377 | $61K | |
| 64494 | 4.4% | 2,284 | 828 | $55K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.0% | 2,620 | 2,214 | $50K |
| 64483 | 3.6% | 300 | 237 | $46K | |
| 64484 | 3.3% | 577 | 236 | $41K |
29 more codes
| 64490 | 1.3% | 290 | $16K | |
| 64491 | <1% | 288 | $11K | |
| 64492 | <1% | 244 | $9K | |
| 62323 | <1% | 156 | $9K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 158 | $9K |
| 20550 | <1% | 372 | $6K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 695 | $6K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 32 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 209 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,309 | $1K |
| 72202 | <1% | 85 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,044 | $889.46 |
| 85610 | <1% | 177 | $810.00 | |
| 36416 | <1% | 276 | $430.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 15 | $229.88 |
| 94760 | <1% | 6,551 | $1.98 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,348 | $0.06 |
| 1100F | 0% | 1,425 | $0.00 | |
| 3288F | 0% | 3,684 | $0.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 4,400 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 3,051 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 1,313 | $0.00 |
| 0518F | 0% | 3,414 | $0.00 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 90 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 32 | $0.00 |
| 6045F | 0% | 1,471 | $0.00 | |
| 4004F | 0% | 32 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 200 | $0.00 |
| 1036F | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSAVAGE-EDWARDS, BELINDA (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Rehabilitation & Neurological Services LLC | Huntsville, AL | $84K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.